ipilimumab + interleukin-2

Ipilimumab + interleukin-2 is a combination immunotherapy regimen used primarily in the treatment of advanced or metastatic melanoma. Ipilimumab is a monoclonal antibody that targets cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), functioning as an immune checkpoint inhibitor to enhance T-cell activation and proliferation. Interleukin-2 (IL-2) is a cytokine therapy that stimulates the growth and activity of T cells, further promoting anti-tumor immune responses. The combination leverages complementary mechanisms—checkpoint inhibition by ipilimumab and immune activation by IL-2—to potentially improve clinical outcomes in patients who have progressed on other therapies, such as anti-PD1 agents. Clinical studies have shown this regimen can induce durable responses in some patients but is associated with significant toxicity requiring careful management[2][3][6][7][8].

Brand names

YervoyProleukin

Other names

Interleukin-2Interleukin2Interleukin 2IL-2IL2IL 2aldesleukinipilimumab